Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges

No disease-modifying therapies (DMT) for neurodegenerative diseases (NDs) have been established, particularly for Alzheimer's disease (AD) and Parkinson's disease (PD). It is unclear why candidate drugs that successfully demonstrate therapeutic effects in animal models fail to show disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dana, Kim, Young-Sam, Shin, Dong Wun, Park, Chang-Shin, Kang, Ju-Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Neurological Association 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063862/
https://www.ncbi.nlm.nih.gov/pubmed/27819412
http://dx.doi.org/10.3988/jcn.2016.12.4.381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063862/
https://www.ncbi.nlm.nih.gov/pubmed/27819412
http://dx.doi.org/10.3988/jcn.2016.12.4.381

Ejemplares similares